[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disease Prediction

Migration, Crosslink

📖

[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disease Prediction

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-flornaptitril-pet-a

📖 Wiki Page

clinical2349 wordssynced 2026-04-02

[F-18]Flornaptitril PET — Phase 3 Tau Imaging for Alzheimer's Disease

Clinical Trial Identifier: [NCT06254469](https://clinicaltrials.gov/study/NCT06254469)

Trial Overview

flowchart TD clinical_trials_flornaptitril_["F-18Flornaptitril PET - Phase 3 for Alzheimer"] style clinical_trials_flornaptitril_ fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_flor_0["Trial Overview"] clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_0 style clinical_trials_flor_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_flor_1["Key Information"] clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_1 style clinical_trials_flor_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_flor_2["Background and Rationale"] clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_2 style clinical_trials_flor_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_flor_3["The Importance of Tau Imaging in Alzheimers Dis"] clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_3 style clinical_trials_flor_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_flor_4["Current Limitations of Tau PET"] clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_4 style clinical_trials_flor_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_flor_5["Mechanism of Action"] clinical_trials_flornaptitril_ -->|"includes"| clinical_trials_flor_5 style clinical_trials_flor_5 fill:#81c784,stroke:#333,color:#000

...

[F-18]Flornaptitril PET — Phase 3 Tau Imaging for Alzheimer's Disease

Clinical Trial Identifier: [NCT06254469](https://clinicaltrials.gov/study/NCT06254469)

Trial Overview

Mermaid diagram (expand to render)

[F-18]Flornaptitril (also known as 18F-MK-6240) is a novel fluorine-18 labeled PET radiotracer developed by CereMark Pharma for imaging tau pathology in Alzheimer's disease and other tauopathies. This Phase 3 clinical trial evaluates its utility in predicting Alzheimer's disease progression and differentiating between various tauopathies.

This trial represents a critical step forward in precision medicine for neurodegenerative diseases, where accurate tau pathology detection enables better diagnostic stratification, prognostic counseling, and treatment selection.

Key Information

| Field | Value |
|-------|-------|
| NCT Number | NCT06254469 |
| Phase | Phase 3 |
| Status | Recruiting |
| Sponsor | CereMark Pharma |
| Condition | Alzheimer's Disease, Cognitively Normal |
| Participants | 230 |
| Intervention | [F-18]Flornaptitril PET scan |
| Primary Outcome | Tau deposition quantification |
| Study Duration | 24 months |
| Imaging Timepoints | Baseline, 12 months, 24 months |

Background and Rationale

The Importance of Tau Imaging in Alzheimer's Disease

Alzheimer's disease (AD) is characterized by two hallmark protein pathologies: amyloid-beta (Aβ) plaques and neurofibrillary tau tangles (NFTs). While amyloid deposition begins decades before clinical symptoms, it is the tau pathology that more closely correlates with clinical impairment and disease progression[@devous2002].

Tau is a microtubule-associated protein that stabilizes axonal microtubules. In AD, tau becomes hyperphosphorylated, aggregates into paired helical filaments (PHFs), and forms neurofibrillary tangles within neurons. The spread of tau pathology follows a predictable pattern—beginning in the entorhinal cortex and progressing to the hippocampus and neocortex—mirroring the clinical progression of cognitive decline[@scholl2017].

Key reasons tau PET imaging is crucial:

Tau Correlates with Cognition: NFT burden correlates more strongly with cognitive impairment than amyloid burden. Studies show that regional tau deposition predicts rate of cognitive decline more accurately than amyloid measures[@cope2018].

Disease Staging: Tau PET enables in vivo staging of Alzheimer's disease, providing information about disease severity and prognosis that amyloid imaging alone cannot[@jack2018].

Differential Diagnosis: Different tauopathies have distinct regional patterns of tau deposition. AD typically shows neocortical and limbic tau, while progressive supranuclear palsy (PSP) shows basal ganglia and brainstem patterns, and corticobasal syndrome (CBS) shows asymmetric cortical involvement[@mott2016].

Therapeutic Development: Tau PET is essential for:

Enriching clinical trials with patients who have tau pathology
Monitoring treatment response to anti-tau therapies
Demonstrating target engagement for tau-targeting drugs

Current Limitations of Tau PET

First-generation tau PET tracers (notably flortaucipir, also known as AV-1451 or Tauvid) have shown excellent performance in AD but face limitations:

Off-target binding: Non-specific binding in basal ganglia and other regions
Limited differentiation of 3R vs 4R tau: Cannot distinguish AD (mixed 3R/4R) from pure 4R tauopathies
Blood pool artifact: High signal in vascular compartments
Limited utility in non-AD tauopathies: Not optimized for PSP, CBD, or other 4R tauopathies

Flornaptitril was developed to address some of these limitations, with improved binding selectivity and kinetics.

Mechanism of Action

Tau PET Imaging Principles

Flornaptitril is a fluorine-18 labeled small molecule that crosses the blood-brain barrier and binds selectively to tau protein aggregates:

Target: Hyperphosphorylated tau protein in neurofibrillary tangles (NFTs)
Binding Site: Specific to paired helical filament (PHF) tau conformation
Selectivity: Preferential binding to PHF over amyloid-beta plaques
Signal Generation: F-18 emission (half-life 110 minutes) detected via PET imaging

Binding Characteristics

| Property | Flornaptitril | Flortaucipir |
|----------|-------------|-------------|
| Ki (PHF tau) | ~1 nM | ~1 nM |
| Amyloid selectivity | >10-fold | ~2-fold |
| Brain kinetics | Fast | Moderate |
| Off-target | Lower | Higher (basal ganglia) |

The Neurobiological Basis

The selective binding of Flornaptitril to PHF tau reflects the unique conformation of tau filaments in different diseases:

Alzheimer's disease (AD): Mixed 3R + 4R tau in paired helical filaments
Progressive supranuclear palsy (PSP): Primarily 4R tau in straight filaments
Corticobasal degeneration (CBD): 4R tau in astrocytic plaques
Chronic traumatic encephalopathy (CTE): 3R + 4R tau in NFTs

The ability to differentiate these conformations could enable accurate differential diagnosis, which is currently challenging clinically.

Differentiation from Other Tauopathies

One of Flornaptitril's potential advantages is the ability to help differentiate AD tau from other tauopathies:

| Tauopathy | Characteristic Tau Type | Typical Pattern |
|-----------|------------------------|------------------|
| Alzheimer's Disease | 3R/4R PHF | Entorhinal cortex → Hippocampus → Neocortex |
| Progressive Supranuclear Palsy | 4R | Basal ganglia, brainstem, cerebellar |
| Corticobasal Syndrome | 4R | Asymmetric frontoparietal cortex |
| Chronic Traumatic Encephalopathy | 3R/4R | Deep brain structures, cortex |

The ability of Flornaptitril to potentially differentiate CTE from AD is particularly significant, as current tracers cannot reliably make this distinction.

Study Design

Trial Objectives

Primary:

Assess diagnostic performance of Flornaptitril PET for AD prediction
Evaluate sensitivity and specificity for detecting tau pathology
Determine optimal quantification approaches

Secondary:

Compare with established tau PET tracers (flortaucipir)
Assess correlation with cognitive measures (MMSE, CDR)
Evaluate utility in differentiating AD from other tauopathies
Establish longitudinal change metrics

Imaging Protocol

| Parameter | Specification |
|-----------|--------------|
| Dose | 185-370 MBq (5-10 mCi) Flornaptitril IV |
| Scan start | 30-40 minutes post-injection |
| Duration | 20 minutes |
| Reconstruction | OSEM with attenuation correction |
| Regions | Cortical VOIs (frontal, temporal, parietal, occipital, ACC) |

Inclusion Criteria

Age 50-85 years
Cognitively normal (CDR 0) or mild cognitive impairment (CDR 0.5)
Ability to undergo PET imaging
No significant neurological conditions (except AD)
MMSE score ≥ 20
Fluent in English or local language

Exclusion Criteria

Contraindications to PET imaging (radiation allergy, claustrophobia)
Active psychiatric conditions (major depression, psychosis)
Significant brain pathology other than AD (infarcts, tumors)
Current substance abuse
Metallic implants (MRI incompatible)

Participant Stratification

The trial enrolls participants in three groups:

Cognitively Normal, Tau-negative (n=80): Control group

Cognitively Normal or MCI, Tau-positive (n=90): Preclinical/early AD

Clinical AD (n=60): Mild-to-moderate AD dementia

Study Procedures

Baseline Visit:

Medical and neurological examination
Cognitive testing (MMSE, CDR, neuropsychological battery)
MRI brain scan
PET imaging session (90-minute dynamic scan)
CSF collection (optional, for biomarker substudy)

Follow-up:

Repeat PET imaging at 12 and 24 months
Cognitive assessments at 6-month intervals
Safety monitoring throughout

Comparison with Existing Tau PET Tracers

Current Tau PET Tracer Landscape

| Tracer | Developer | Target | Status | Key Features |
|--------|-----------|--------|--------|-------------|
| Flortaucipir (AV-1451) | Eli Lilly | PHF-tau | Approved | First approved, validated in AD |
| Flornaptitril | CereMark Pharma | PHF-tau | Phase 3 | Potential CTE differentiation |
| PI-2620 | AC Immune/Roche | 4R-tau | Phase 2 | PSP/CBD specificity |
| APN-1607 (Lifecann) | Aprinoia | PHF-tau | Phase 2 | Broader detection |
| MK-6240 | Merck | PHF-tau | Phase 2 | High specificity |

Advantages of Flornaptitril

Improved Target-to-Background Ratio: Early data suggest improved signal-to-noise compared to first-generation tracers

Broader Tauopathy Coverage: Designed to detect multiple tauopathy subtypes

CTE Differentiation: Potential to differentiate chronic traumatic encephalopathy from AD

Off-Target Reduction: Modified structure to reduce off-target binding

Clinical Significance and Applications

Early Detection and Prevention

One of the most promising applications of tau PET is identifying individuals with preclinical AD:

Preclinical AD Detection:

Cognitively normal individuals with positive tau PET have higher risk of progression to MCI/AD
Tau PET positivity may occur before significant cognitive decline
Enables identification of individuals who might benefit from early intervention

Risk Stratification:

Tau burden provides information beyond amyloid for predicting progression
Regional tau patterns indicate likely clinical phenotype
Combined with amyloid PET, enables comprehensive pathology assessment

Differential Diagnosis

Tau PET has become essential for differentiating neurodegenerative conditions:

AD vs. Other Dementias:

Distinguishing AD from frontotemporal dementia
Differentiating AD from vascular dementia
Identifying mixed pathology

Tauopathies:

Distinguishing AD from PSP
Differentiating AD from CBS
Identifying primary age-related tauopathy (PART)

Clinical Trial Enrichment

Tau PET is increasingly used in clinical trials for:

Patient Enrichment: Selecting patients with confirmed tau pathology for anti-tau therapy trials

Target Engagement: Demonstrating drug binding to tau in the brain

Treatment Response: Monitoring changes in tau burden over time

Safety Considerations

Radiation Exposure

PET imaging involves exposure to ionizing radiation:

Typical effective dose from one [F-18]Flornaptitril scan: ~5-7 mSv
Cumulative dose from three scans over 24 months: ~15-21 mSv
This is comparable to other nuclear medicine procedures and within safe limits

Contraindications

Absolute Contraindications:

Pregnancy
Breastfeeding (pause for 24 hours post-injection)
Unable to lie still for 90 minutes

Relative Contraindications:

Severe claustrophobia (consider open MRI)
Metal implants that may cause artifacts

Adverse Events

[F-18]Flornaptitril has been well-tolerated in Phase 1/2 studies:

Injection site reactions: rare
Headache: uncommon
Nausea: rare
Allergic reactions: very rare

Industry Context

CereMark Pharma

CereMark Pharma is a biotechnology company focused on precision diagnostics for neurodegenerative diseases. Their pipeline includes:

Tau PET tracers: Flornaptitril (AD), subsequent candidates for PSP/CBD
Alpha-synuclein tracers: In development for Parkinson's disease
Companion diagnostics: For anti-tau therapeutic programs

Competitive Landscape

| Company | Tracer | Development Stage |
|--------|--------|------------------|
| CereMark | Flornaptitril | Phase 3 |
| Eli Lilly | Flortaucipir | Approved |
| AbbVie | PI-2620 | Phase 2 |
| Life Molecular | LTE | Phase 1 |

Market Impact

Tau PET imaging represents a significant market opportunity:

Global Tau PET Market: ~$800M annually
Growth Drivers: Alzheimer's prevalence, clinical trial demand, precision medicine
Competitive Landscape: 5+ companies developing next-gen tau tracers
Reimbursement: Active discussion for Medicare coverage in 2026

Participant Experience

Imaging Protocol

The Flornaptitril PET scan follows a standardized protocol:

Radiotracer Administration: ~185 MBq (5 mCi) IV injection

Scan Window: 80-100 minutes post-injection

Duration: 20-minute acquisition

Repeat: Baseline and 12-month follow-up scans

Safety Monitoring: Vital signs before and after scan

Participant Burden

Total Time: ~2.5 hours per visit
Radiation Dose: ~3.5 mSv per scan (comparable to CT)
Repeat Scans: Two visits over 12 months
Cognitive Testing: Included in each visit (~45 minutes)

Future Directions

Flornaptitril PET is designed to work alongside:

Amyloid PET (Pittsburgh compound B): Confirms amyloid pathology
FDG-PET: Assesses glucose metabolism
MRI: Structural anatomy
CSF biomarkers: Tau, amyloid protein levels
Blood-based biomarkers: Promise for screening

Combined Scoring Systems

The integration of multiple biomarkers enables:

AT(N) classification: Amyloid, Tau, Neurodegeneration system
Biological definition of AD: Amyloid + tau pathology
Stage-appropriate interventions: Match treatment to disease stage

Post-Trial Research Opportunities

Regardless of trial outcome, this research will inform:

Optimal Imaging Protocols: Determining ideal scan timing and analysis methods

Quantitative Metrics: Standardizing SUVR measurements and cutoff values

Longitudinal Changes: Characterizing tau accumulation rates in different populations

Current Status

This trial is actively recruiting. For more information:

ClinicalTrials.gov: [NCT06254469](https://clinicaltrials.gov/study/NCT06254469)
CereMark Pharma: www.cermarkpharma.com
Contact: clinicaltrials@cermarkpharma.com

Technical Specifications

Radiotracer Properties

| Property | Value |
|----------|-------|
| Radioisotope | Fluorine-18 |
| Half-life | 109.7 minutes |
| Production | Cyclotron |
| Specific activity | >100 GBq/μmol |
| Formulation | Sterile solution for IV injection |

Imaging Protocol

PET Acquisition:

Dynamic scan for 90-120 minutes
Standardized uptake value (SUV) calculations
Distribution volume (VT) modeling

MR Reference:

T1-weighted MRI for anatomical segmentation
Atrophy correction for partial volume effects

Competitive Landscape

Tau PET Tracer Comparison

| Tracer | Target | 3R/4R Specificity | FDA Status | Key Limitation |
|--------|--------|-------------------|------------|----------------|
| Flortaucipir (AV-1451) | PHF tau | Mixed | Approved (AD) | Off-target binding |
| Flornaptitril | PHF tau | Mixed | Phase 3 | CTE differentiation |
| PI-2620 | 4R tau | 4R-specific | Phase 2 | Limited AD signal |
| MK-6240 | PHF tau | Mixed | Phase 3 | Unknown |
| JNJ-068 | 4R tau | 4R-specific | Phase 1 | Early development |

Market Opportunity

The global tau PET imaging market is projected to grow significantly:

Current AD diagnostics rely heavily on amyloid PET
Tau PET provides superior correlation with cognitive decline
Differential diagnosis remains unmet need
Clinical trial enrichment drives demand

Future Directions

Clinical Applications

Prognostic stratification: Tau burden predicts rate of cognitive decline

Treatment monitoring: Anti-tau therapy response assessment

Patient selection: Tau-positive enrichment for clinical trials

Differential diagnosis: Distinguishing AD from FTD spectrum

Research Applications

Neuropathology correlation: Validating in vivo tau detection
Longitudinal studies: Tracking tau spread patterns
Treatment development: Surrogate endpoint for disease modification

Biomarkers and Diagnostics

[Tau PET Imaging for CBS and PSP](/biomarkers/tau-pet-cbs-psp)
[Tau PET Tracers and Filament Structures](/mechanisms/tau-filament-structures-cryo-em)
[Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-disease-biomarkers)
[Amyloid PET Imaging](/biomarkers/amyloid-pet-imaging)

Mechanisms

[Tauopathies Comparison Matrix](/mechanisms/tauopathies-comparison-matrix)
[Tau Hyperphosphorylation in AD](/mechanisms/tau-hyperphosphorylation-ad)
[Neurofibrillary Tangle Formation](/mechanisms/nft-formation-ad)

Clinical Trials

[Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease)
[Phase 3 AD Trials](/clinical-trials/phase-3-ad-trials)

External Links

[ClinicalTrials.gov NCT06254469](https://clinicaltrials.gov/study/NCT06254469)
[CereMark Pharma](https://www.cermarkpharma.com/)
[Alzheimer's Association](https://www.alz.org/)
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)

References

[NCT06254469: Flornaptitril PET in Prediction of Alzheimer's Disease](https://clinicaltrials.gov/study/NCT06254469)

[Scholl et al., PET Imaging of Tau Deposition in the Aging Brain (2017)](https://doi.org/10.1016/j.neuron.2016.08.022)

[Jack et al., Longitudinal tau PET in aging and Alzheimer's disease (2018)](https://doi.org/10.1002/ana.25227)

[De Vos et al., Tau imaging in neurodegenerative disease (2002)](https://doi.org/10.1136/jnnp.73.2.166)

[Mott et al., Tauopathies: classification and clinical approach (2016)](https://doi.org/10.1038/nrneurol.2016.30)

[Kolb et al., Properties of [18F]APN-1607 as a tau PET tracer (2016)](https://doi.org/10.2967/jnumed.119.235654)

[Smith et al., 18F-AV-1457 corresponds to PET in vivo tau pathology in AD (2016)](https://doi.org/10.1093/brain/aww233)

[Leuzy et al., Tau PET imaging in neurodegenerative tauopathies (2019)](https://doi.org/10.1038/s41582-019-0237-9)

[Cope et al., Tau burden determines age-related cognitive decline (2018)](https://doi.org/10.1093/brain/awy316)

[Cho et al., Synthesis and evaluation of tau PET tracers (2016)](https://doi.org/10.1021/acs.jmedchem.6b01020)

[Schoon et al., Tau PET imaging: past, present and future (2019)](https://pubmed.ncbi.nlm.nih.gov/30647305/)

[Marsh et al., Tau PET tracers in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33850389/)

📖 View canonical wiki page →

Related Entities

clinical-trials-flornaptitril-pet-alzheimers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-flornaptitril-pet-alzheimers
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2f6235578b2d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-flornaptitril-pet-alzheimers'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

506

Outgoing

515

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disease Prediction

[F-18]Flornaptitril PET — Phase 3 Tau Imaging for Alzheimer's Disease

Trial Overview

[F-18]Flornaptitril PET — Phase 3 Tau Imaging for Alzheimer's Disease

Trial Overview

Key Information

Background and Rationale

The Importance of Tau Imaging in Alzheimer's Disease

Current Limitations of Tau PET

Mechanism of Action

Tau PET Imaging Principles

Binding Characteristics

The Neurobiological Basis

Differentiation from Other Tauopathies

Study Design

Trial Objectives

Imaging Protocol

Inclusion Criteria

Exclusion Criteria

Participant Stratification

Study Procedures

Comparison with Existing Tau PET Tracers

Current Tau PET Tracer Landscape

Advantages of Flornaptitril

Clinical Significance and Applications

Early Detection and Prevention

Differential Diagnosis

Clinical Trial Enrichment

Safety Considerations

Radiation Exposure

Contraindications

Adverse Events

Industry Context

CereMark Pharma

Competitive Landscape

Market Impact

Participant Experience

Imaging Protocol

Participant Burden

Future Directions

Integration with Multi-modal Biomarkers

Combined Scoring Systems

Post-Trial Research Opportunities

Current Status

Technical Specifications

Radiotracer Properties

Imaging Protocol

Competitive Landscape

Tau PET Tracer Comparison

Market Opportunity

Future Directions

Clinical Applications

Research Applications

Related Pages

Biomarkers and Diagnostics

Mechanisms

Clinical Trials

See Also

External Links

References

💬 Discussion